Nuclear Diagnostic Products

What Nuclear Diagnostic Products does

PharmaLogic (the operating trade name of Nuclear Diagnostic Products, formally PharmaLogic Holdings Corp.) is a private radiopharmaceutical services company headquartered in Rockaway, New Jersey, founded in 1999 with 11–50 employees. The company operates as a contract development and manufacturing organization (CDMO/CMO) serving pharmaceutical sponsors that require specialized capabilities to advance diagnostic and therapeutic radiopharmaceutical products from clinical development through commercial launch. Its offering is structured around four interconnected service lines: CDMO Services providing CMC (Chemistry, Manufacturing, and Controls) and technical capabilities across the drug lifecycle; CMO Diagnostics for contract manufacturing of diagnostic radiopharmaceuticals; CMO Therapeutics for contract manufacturing of therapeutic radiopharmaceuticals, including novel Actinium-225 (Ac-225) based compounds; and Supply Chain & Radiopharmacy services for distribution and delivery. Underlying technology includes PET (Positron Emission Tomography) radiopharmaceutical manufacturing, Ac-225 production, and integrated radiopharmacy operations, with manufacturing infrastructure including a newly opened PET facility in Atlanta, Georgia (April 2026).

The company's core technology stack is rooted in radiopharmaceutical chemistry, manufacturing controls (CMC), and capital-intensive specialized production infrastructure rather than software or AI/ML. Customer-facing channels are B2B-oriented: a corporate website with service pages and a direct-order portal (including WebOlo ordering), a LinkedIn corporate presence, and press/news distribution for major announcements. Go-to-market is enterprise field sales targeting pharmaceutical companies that lack internal radiopharmaceutical manufacturing infrastructure, with revenue generated through long-term manufacturing contracts (recurring/contract CDMO economics) and managed distribution services for radiopharmacy logistics.

The company's revenue model is B2B contract manufacturing with quote-based pricing (no published pricing); the primary customer segment is "Pharmaceutical Companies (Sponsors)" seeking CMC and technical capabilities, segmented horizontally by therapeutic intent (diagnostic vs. therapeutic). Named customer engagement disclosed in source materials is with Ratio Therapeutics, for which PharmaLogic is manufacturing the Ac-225-based therapeutic RTX-2358 for a Phase 1/2 FAP-targeted radiopharmaceutical study in late-stage aggressive sarcomas. Operating geography is currently described as the Southeast United States, with the Atlanta facility representing its most recently disclosed geographic footprint expansion. No funding rounds, M&A activity, ownership/PE backing, or leadership team details are disclosed in available source material.

Name

Nuclear Diagnostic Products

Legal name

PharmaLogic

Website

https://ndprx.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

PharmaLogic (DBA of Nuclear Diagnostic Products) is a private US radiopharmaceutical CDMO/CMO serving pharmaceutical sponsors with CMC capabilities, diagnostic and therapeutic radiopharmaceutical manufacturing, and integrated radiopharmacy distribution.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)

akta.pro primary industry

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)

akta.pro secondary industries

Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Radiopharmaceutical manufacturing
• CDMO services
• Diagnostic radiopharmaceuticals
• Therapeutic radiopharmaceuticals
• Radiopharmacy services

Headquarters

HQ city

Rockaway

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Infrastructure, Operations, Personnel, Technology or R&D, Supply Chain

Revenue model

1. CDMO/CMO Services: Contract development and manufacturing organization services providing pharmaceutical sponsors with CMC and technical capabilities to advance radiopharmaceutical products from clinical development through commercialization. Revenue is generated through long-term manufacturing contracts with pharmaceutical companies.
2. Supply Chain & Radiopharmacy Services: Integrated supply chain and radiopharmacy distribution services for diagnostic and therapeutic radiopharmaceuticals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Nuclear Diagnostic Products (operating as PharmaLogic) provides contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) services for diagnostic and therapeutic radiopharmaceuticals. The company delivers CMC and technical capabilities to support pharmaceutical sponsors in advancing radiopharmaceutical drug products from clinical development through commercial launch, complemented by integrated supply chain and radiopharmacy distribution services.

Product overview

PharmaLogic is a radiopharmaceutical services company offering a unified portfolio of four interconnected service lines. The core offering consists of CDMO Services (contract development and manufacturing) which provides CMC and technical capabilities for drug development from clinical through commercial stages. This is complemented by two CMO service lines—CMO Diagnostics for diagnostic radiopharmaceutical manufacturing and CMO Therapeutics for therapeutic radiopharmaceutical manufacturing. Additionally, Supply Chain & Radiopharmacy services ensure efficient distribution and delivery of products. Together, these services enable pharmaceutical companies to advance products from clinical development to commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• CDMO Services Contract development and manufacturing organization services providing CMC (Chemistry, Manufacturing, and Controls) and technical capabilities to support pharmaceutical sponsors in advancing radiopharmaceutical drug development from clinical development through commercial launch.
• CMO Diagnostics Contract manufacturing organization services specializing in diagnostic radiopharmaceuticals for imaging applications, including PET radiopharmaceutical manufacturing.
• CMO Therapeutics Contract manufacturing organization services specializing in therapeutic radiopharmaceuticals for treatment applications, including novel Actinium-225 (Ac-225) based therapeutics.
• Supply Chain & Radiopharmacy Comprehensive supply chain management and radiopharmacy services enabling efficient distribution and delivery of radiopharmaceutical products to end users.

Quantifiable outcome

• First cohort dosing successfully completed for Ratio Therapeutics Phase 1/2 study

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Ratio TherapeuticscoreStrategic or Co-development Partner · 29 May 2026PharmaLogic and Ratio Therapeutics expanded their manufacturing collaboration to support clinical development of Ac-225 RTX-2358. Additionally, PharmaLogic announced successful supply of the first cohort dosing for Ratio Therapeutics' Phase 1/2 study of a novel FAP-targeted radiopharmaceutical in late-stage aggressive sarcomas (December 2025). The partnership involves manufacturing of Actinium-225 based therapeutic radiopharmaceuticals.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• IBA Radiopharma Solutions: Provides radiopharma production facilities, isotope supply, and contract manufacturing services, competing for the same CDMO/CMO sponsor business for both diagnostic and therapeutic radiopharmaceuticals.
• PETNET Solutions (Siemens Healthineers): Largest US PET radiopharmaceutical manufacturing and distribution network, directly competing with PharmaLogic's CMO Diagnostics and Supply Chain & Radiopharmacy offerings for sponsor and hospital customers.
• Cardinal Health Nuclear & Precision Health Solutions: Operates the largest radiopharmacy network in the US, directly comparable to PharmaLogic's radiopharmacy distribution and supply chain services for diagnostic radiopharmaceuticals.
• Curium Pharma: Global nuclear medicine company providing diagnostic and therapeutic radiopharmaceutical manufacturing, closely overlapping with PharmaLogic's CDMO/CMO Diagnostics and CMO Therapeutics services.
• ABX Advanced Biochemical Compounds: Specialized CDMO for radiopharmaceutical precursors and finished doses; comparable in scale and niche focus to PharmaLogic's CDMO and CMO Diagnostics offerings.
• ITM Isotope Technologies Munich: CDMO specializing in therapeutic and diagnostic radioisotopes including lutetium-177 and actinium-225, directly comparable to PharmaLogic's emerging Ac-225 therapeutic manufacturing focus.

Broad incumbents

• GE HealthCare (Radiopharmaceuticals): Major incumbent across imaging and radiopharma (including SOFIE Biosciences), with broad manufacturing and distribution capabilities that overlap with PharmaLogic's diagnostic and therapeutic CMO offerings.
• Bayer (Radiology / Curium JV): Through its stake in Curium and broader radiology franchise, Bayer competes for the same sponsor and hospital customers for diagnostic and therapeutic radiopharmaceutical manufacturing.
• Lantheus Holdings: Established diagnostic radiopharmaceutical company with proprietary products (e.g., Pylarify, Definity) and emerging therapeutic programs; broader portfolio than PharmaLogic but operates in the same radiopharma value chain.

Emerging players

• Telix Pharmaceuticals: Theranostic radiopharmaceutical sponsor with growing commercial and clinical assets (e.g., Illuccix); serves as both a potential customer for CDMOs like PharmaLogic and an emerging competitor for Ac-225/Lu-177 programs.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/nuclear-diagnostic-products

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuclear Diagnostic Products